Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia [EARLY_Phase 1]
This early-phase (Phase 1) clinical trial evaluates the safety and potential efficacy of CI-135, a FLT3-targeted CAR-T cell therapy, for rel…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT
This clinical trial registry entry describes a study evaluating whether donor selection affects graft-versus-host disease prophylaxis outcom…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT [Phase 2]
Phase 2 trial assessing the combination of venetoclax and decitabine in patients aged 60 to 74 with newly diagnosed acute myeloid leukemia e…
-
CLINICAL_TRIALS other · 2025-01-06Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML [NA]
A ClinicalTrials.gov entry describes using mitoxantrone hydrochloride liposome with busulfan and cyclophosphamide as a conditioning regimen …
-
FDA label_change · 2025-01-03FDA Approved: DOXORUBICIN HYDROCHLORIDE — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for doxorubicin hydrochloride from Zydus Lifesciences Limited, updating the labeling for the product…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis [Phase 2, Phase 3]
A multi-agent trial in pediatric and young adult patients explores preventing graft-versus-host disease after transplantation using post-tra…
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia [NA]
A clinical trial evaluating immediate allogeneic hematopoietic stem cell transplantation versus re-treatment for patients with high-risk acu…
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS [Phase 1]
Nkarta's NKX101 is an intravenous allogeneic CAR-NK cell therapy being studied in adults with relapsed/refractory acute myeloid leukemia and…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML [Phase 2]
Phase 2 clinical trial evaluating the safety and efficacy of a liposome-encapsulated mitoxantrone regimen for relapsed or refractory acute m…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial evaluating FF-10101-01 in adults with relapsed or refractory acute myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2024-12-24Clinical Trial Update: BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study evaluating BN104 in combination with chemotherapy or targeted agents for Acute Myeloid …
-
CLINICAL_TRIALS research · 2024-12-20Clinical Trial Update: GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG [Phase 3]
Phase 3 randomized trial comparing post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prophylaxis…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors [Phase 1, Phase 2]
Clinical trial evaluating idasanutlin in combination with chemotherapy or venetoclax in pediatric and young adult relapsed/refractory acute …
-
FDA approval · 2024-12-19FDA Approved: AZACITIDINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for azacitidine submitted by BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS [Phase 1, Phase 2]
A Phase Ib/II multicenter open-label study of bemcentinib (BGB324) in acute myeloid leukemia or myelodysplastic syndromes has completed and …
-
FDA approval · 2024-12-19FDA Approved: CYCLOPHOSPHAMIDE — Original Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' original ANDA for cyclophosphamide, establishing a generic version of the chemotherapy agent.
-
CLINICAL_TRIALS research · 2024-12-19Clinical Trial Update: Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML [Phase 3]
This registry entry notes a Phase 3 study (SCRIPT-AML) evaluating a conditioning regimen for pediatric acute myeloid leukemia patients under…
-
FDA label_change · 2024-12-18FDA Approved: IDHIFA — Supplemental Application (Celgene Corporation)
The document reports a Celgene supplemental application for IDHIFA (enasidenib mesylate) submitted to the FDA. It relates to updating the pr…
-
CLINICAL_TRIALS research · 2024-12-18Clinical Trial Update: COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [NA]
A feasibility study on coaching and prehabilitation for patients with acute myeloid leukemia and myelodysplastic syndromes, sponsored by Ins…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS [Phase 1]
A Phase 1 study of FD-001 in recurrent/refractory acute myeloid leukemia, non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndro…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy [Phase 3]
Phase 3 clinical trial update comparing gilteritinib versus midostaurin in combination with induction, consolidation, and maintenance in adu…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
A biomarker-directed Phase 2 trial of tamibarotene (SY-1425) in acute myeloid leukemia and myelodysplastic syndrome has completed and posted…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma [Phase 2]
Phase 2 trial evaluating dendritic cell therapy for acute myeloid leukemia, chronic myeloid leukemia, and multiple myeloma reports efficacy …
-
CLINICAL_TRIALS trial_result · 2024-12-12Clinical Trial Update: Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia [Phase 1]
Phase 1 trial of fludarabine, cytarabine, and pegcrisantaspase for relapsed or refractory leukemias was terminated; the update notes the stu…